おすすめの製品
由来生物
goat
品質水準
リコンビナント
expressed in goat
抗体製品の状態
fractionated antiserum
抗体製品タイプ
primary antibodies
クローン
polyclonal
フォーム
lyophilized
分子量
antigen 65 kDa
交差性
human
包装
vial of 2 mL lyophilized antiserum
テクニック
immunocytochemistry: suitable
immunohistochemistry: suitable
UniProtアクセッション番号
保管温度
2-8°C
遺伝子情報
human ... ALB(213)
関連するカテゴリー
詳細
Albumin, the major protein produced by liver cells, represents more than half of the total protein content of human serum. Many other body fluids also contain albumin. Three major functions for serum albumin have been proposed: maintenance of osmotic pressure, transportation of a variety of substances and an endogenous source of amino acids. The primary sites of albumin degradation are not known, but the protein can be metabolized by almost every organ in the body. Determination of serum albumin levels is a widely used screening test in clinical medicine. A decrease in serum albumin levels may indicate disease states such as malnutrition, cirrhosis, nephrotic syndrome, diabetes, gastrointestinal and hepatic diseases, thermal burns and pulmonary disease.
Goat polyclonal anti-Albumin antiserum is immunospecific for human albumin by immunoelectrophoresis against normal human serum and human albumin. Identity and purity of the specific antibody is established by immunoelectrophoresis (IEP). Electrophoresis of the antiserum followed by diffusion against anti-goat serum results in multiple arcs of precipitation, whereas against anti-goat IgG, it results in a single arc of precipitation in the γ region.
免疫原
purified human albumin
アプリケーション
Goat polyclonal anti-Albumin antiserum is used to tag albumin for detection and quantitation by immunocytochemical and immunohistochemical (IHC) techniques. It is used as a probe to determine the presence and roles of albumin a variety of clinical indications.
物理的形状
Lyophilized from 0.01 M phosphate buffered saline, pH 7.2
免責事項
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
適切な製品が見つかりませんか。
製品選択ツール.をお試しください
保管分類コード
11 - Combustible Solids
WGK
WGK 3
引火点(°F)
Not applicable
引火点(℃)
Not applicable
個人用保護具 (PPE)
Eyeshields, Gloves, type N95 (US)
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
A1151-VAR:
A1151-1VL:
A1151-BULK:
A1151-PH:
A1151PROC:
A1151-1VL-PW:
この製品を見ている人はこちらもチェック
Tetsu Akimoto et al.
American journal of physiology. Cell physiology, 284(6), C1625-C1632 (2003-02-28)
We have demonstrated that during culture under 5% O(2,) the addition of recombinant human VEGF or FGF2 to mouse embryonic aorta explants (thoracic level to lateral vessels supplying the mesonephros and metanephros) stimulates microvessel formation. Here we show that microvessel
G Grossmann et al.
Journal of applied physiology (Bethesda, Md. : 1985), 82(6), 2003-2010 (1997-06-01)
Near-term newborn rabbits were exposed via the airways to a monoclonal antibody to surfactant protein B and ventilated for 0-120 min. Control animals received nonspecific rabbit or mouse immunoglobulin G, saline, or no material via the airways. Administration of the
Tetsu Akimoto et al.
Organogenesis, 2(1), 17-21 (2005-01-01)
Hypoxia exists widely in developing embryos where it may regulate blood vessel formation. VEGF and FGF2 produced in developing renal primordia (metanephroi) stimulate microvessel formation from embryonic thoracic aorta cultured under hypoxic conditions (HC) relative to room air (RA). The
Elliott L Rodriguez et al.
Journal of chromatography. A, 1638, 461683-461683 (2020-11-24)
Diabetes is characterized by elevated levels of blood glucose, which can result in the modification of serum proteins. The modification of a protein by glucose, or glycation, can also lead to the formation of advanced glycated end-products (AGEs). One protein
Mischa R Müller et al.
mAbs, 4(6), 673-685 (2013-05-17)
Advances in recombinant antibody technology and protein engineering have provided the opportunity to reduce antibodies to their smallest binding domain components and have concomitantly driven the requirement for devising strategies to increase serum half-life to optimise drug exposure, thereby increasing
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）